Takeda Nycomed AS
Division of Takeda Pharmaceutical Co. Ltd.
www.takedanycomed.no
Latest From Takeda Nycomed AS
Deal Watch: Sandoz Licenses Posimir For Pain As Durect Generates Data For Resubmission
Sandoz acquires rights to extended-release bupivacaine once held by Nycomed and Hospira in deal paying Durect $20m up front. Video interview: Partners Elasmogen and Feldan collaborate with Amgen.
Norway’s Pre Diagnostics Has Alzheimer’s Test In Its Sights
Pre Diagnostics AS is a 2.5-year-old Oslo company developing a blood-based test performed by a GP and sent to a lab for early Alzheimer’s diagnosis.
Verona Adds Two Board Members
Verona Pharma plc, a drug development company focused on respiratory diseases, has appointed Ken Cunningham and Dr. Anders Ullman to its board of directors as non-executive directors – effective Sep. 10, 2015.
Deal Watch: Merck’s Next Move In Cancer Immunotherapy Is BET Inhibitor, Bispecifics Gaining Steam
Pfizer pays Opko $295 million up front for global rights to develop and commercialize a long-acting recombinant human growth hormone, Roche and Novo Nordisk buy into bispecific technology and Janssen signs on with Halozyme, as Pfizer did two years earlier, to use the ENHANZE delivery platform technology with its own candidates against five targets.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Nycomed Pharma AS
- Ownership
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Scandinavia
-
Norway
-
Norway
-
Scandinavia
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Takeda Pharmaceutical Co. Ltd.
- Senior Management
-
Bjorn Small, CEO
Trond Lien, CFO - Contact Info
-
Takeda Nycomed AS
Phone: (47) 66 76 30 30
Drammensveien 852
Asker, 1 383
Norway
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice